{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:48Z","timestamp":1792290768507,"version":"4.4.0"},"reference-count":234,"publisher":"Elsevier","isbn-type":[{"value":"9780443192845","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.acc.2022.09.005","type":"book-chapter","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T12:53:52Z","timestamp":1667566432000},"page":"205-248","source":"Crossref","is-referenced-by-count":20,"title":["Advances in congestive heart failure biomarkers"],"prefix":"10.1016","author":[{"given":"Iyyapu Krishna","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.S. Sai","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Iyyapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunitha","family":"Thirumalasetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Sai","family":"Satish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.acc.2022.09.005_bb0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.CIR.0000025242.79963.4C","article-title":"B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study","volume":"106","author":"McCullough","year":"2002","journal-title":"Circulation"},{"issue":"9081","key":"10.1016\/bs.acc.2022.09.005_bb0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(97)03033-X","article-title":"Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population","volume":"350","author":"McDonagh","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2022.09.005_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10741-014-9438-7","article-title":"Water and sodium in heart failure: a spotlight on congestion","volume":"20","author":"Parrinello","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/bs.acc.2022.09.005_bb0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0030","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/bs.acc.2022.09.005_bb0035","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.healun.2004.07.006","article-title":"Amino terminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure","volume":"23","author":"Rothenburger","year":"2004","journal-title":"J. Heart Lung. Transpl."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11897-018-0375-y","article-title":"An appraisal of biomarker-based risk-scoring models in chronic heart failure: which one is best?","volume":"15","author":"Doumouras","year":"2018","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/bs.acc.2022.09.005_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Olpe","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/bs.acc.2022.09.005_bb0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/CIRCHEARTFAILURE.108.790774","article-title":"Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure","volume":"1","author":"Niederkofler","year":"2008","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0055","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/bs.acc.2022.09.005_bb0060","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ehj.2003.07.005","article-title":"N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure","volume":"24","author":"Gardner","year":"2003","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.hlc.2019.02.004","article-title":"BNP-response to acute heart failure treatment identifies high-risk population","volume":"29","author":"Patel","year":"2020","journal-title":"Heart Lung Circ."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000998","article-title":"Assessment of a University of California, Los Angeles 4-variable risk score for advanced heart failure","volume":"3","author":"Sartipy","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"2016","key":"10.1016\/bs.acc.2022.09.005_bb0075","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0080","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/eurheartj\/ehi631","article-title":"NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients the international collaborative of NT-proBNP study","volume":"27","author":"Januzzi","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0085","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1097\/01.CCM.0000229144.97624.90","article-title":"Comparable increase of B-type natriuretic peptide and aminoterminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure","volume":"34","author":"Rudiger","year":"2006","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0090","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ahj.2004.07.010","article-title":"Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dyspnea in the emergency department (PRIDE) substudy","volume":"149","author":"Krauser","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0095","first-page":"305","article-title":"Natriuretic peptides and their therapeutic potential","volume":"1","author":"Cho","year":"1999","journal-title":"Heart Dis."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jchf.2012.12.003","article-title":"Urinary C-type natriuretic peptide: a new heart failure biomarker","volume":"1","author":"Zakeri","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amjcard.2007.11.019","article-title":"The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level","volume":"101","author":"Baggish","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0110","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archinte.167.4.400","article-title":"Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea","volume":"167","author":"Bayes-Genis","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.acc.2022.09.005_bb0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/hj.1998.v136.89908","article-title":"Elevated B-type natriuretic peptide levels after anthracycline administration","volume":"136","author":"Suzuki","year":"1998","journal-title":"Am. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0120","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14017431.2019.1583363","article-title":"ST2 in heart failure with preserved and reduced ejection fraction","volume":"53","author":"Najjar","year":"2019","journal-title":"Scand. Cardiovasc. J."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0130","volume":"11","author":"O'Meara","year":"2018","journal-title":"Heart Circ Fail."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0135","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCHEARTFAILURE.109.873240","article-title":"Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling","volume":"2","author":"Seki","year":"2009","journal-title":"Circ. Heart Fail."},{"issue":"19","key":"10.1016\/bs.acc.2022.09.005_bb0140","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jacc.2017.09.026","article-title":"Prognostic value of serial ST2 measurements in patients with acute heart failure","volume":"70","author":"van Vark","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","article-title":"High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure","volume":"4","author":"Ky","year":"2011","journal-title":"Heart Fail."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0150","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","article-title":"Identification of serum soluble ST2 receptor as a novel heart failure biomarker","volume":"107","author":"Weinberg","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2022.09.005_bb0155","article-title":"International health informatics study (IHIS) network. Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: a systematic review and meta-analysis","volume":"37","author":"Ip","year":"2021","journal-title":"Int. J. Cardiol. Heart Vasc."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ahj.2006.11.007","article-title":"HF-ACTION trial investigators. Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale","volume":"153","author":"Whellan","year":"2007","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2022.09.005_bb0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/01.RES.0000202804.84885.d0","article-title":"GDF15\/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation","volume":"98","author":"Xu","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2022.09.005_bb0175","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","article-title":"Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure","volume":"50","author":"Kempf","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0180","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cjca.2013.12.010","article-title":"Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction","volume":"30","author":"Izumiya","year":"2014","journal-title":"Can. J. Cardiol."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0185","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ehf2.12301","article-title":"Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15","volume":"5","author":"Bettencourt","year":"2018","journal-title":"ESC Heart Fail."},{"issue":"19","key":"10.1016\/bs.acc.2022.09.005_bb0190","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1097\/CM9.0000000000000449","article-title":"Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study","volume":"132","author":"Ji","year":"2019","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.RES.62.2.191","article-title":"Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor","volume":"62","author":"Edwards","year":"1988","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2022.09.005_bb0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1373\/clinchem.2011.165720","article-title":"Emerging biomarkers in heart failure","volume":"58","author":"van Kimmenade","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2022.09.005_bb0205","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jacc.2010.02.025","article-title":"Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (biomarkers in acute heart failure) trial","volume":"55","author":"Maisel","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0210","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/eurheartj\/ehs136","article-title":"Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea","volume":"33","author":"Shah","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0215","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0220","first-page":"2442","article-title":"Biomarkers and diagnostics in heart failure","volume":"2013","author":"Gaggin","year":"1832","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.acc.2022.09.005_bb0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/000456320103800501","article-title":"Measurement of cardiac troponins","volume":"38","author":"Collinson","year":"2001","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/bs.acc.2022.09.005_bb0230","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/01.CIR.102.10.1193","volume":"102","author":"Braunwald","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2022.09.005_bb0235","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1053\/euhj.2000.2301","article-title":"Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the task force of the European Society of Cardiology","volume":"21","author":"Bertrand","year":"2000","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0240","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/01.CIR.103.3.369","article-title":"Persistently elevated serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes","volume":"103","author":"Sato","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2022.09.005_bb0245","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0002-9343(02)01394-3","article-title":"Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure","volume":"113","author":"Setsuta","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/bs.acc.2022.09.005_bb0250","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/heart.89.6.659","article-title":"Measurement of cardiac troponin I in patients with hypertrophic cardiomyopathy","volume":"89","author":"Sato","year":"2003","journal-title":"Heart"},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb0255","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0260","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehs191","article-title":"Troponin elevation in patients with heart failure: on behalf of the third universal definition of myocardial infarction global task force: heart failure section","volume":"33","author":"Januzzi","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0265","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jchf.2016.02.009","article-title":"Use of high-sensitivity troponin t to identify patients with acute heart failure at lower risk for adverse outcomes: an exploratory analysis from the RELAX-AHF trial","volume":"4","author":"Pang","year":"2016","journal-title":"JACC Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0270","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ejhf.289","volume":"17","author":"Mebazaa","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0275","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.amjcard.2007.07.066","article-title":"Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE","volume":"101","author":"Fonarow","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0280","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jemermed.2003.12.021","article-title":"Outcome of low-risk patients discharged home after a normal cardiac troponin I","volume":"26","author":"Smith","year":"2004","journal-title":"J. Emerg. Med."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0285","first-page":"691","article-title":"The utility of troponin measurement to detect myocardial infarction: review of the current findings","volume":"7","author":"Daubert","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0290","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00395-012-0276-2","article-title":"Chronic creatine kinase deficiency eventually leads to congestive heart failure, but severity is dependent on genetic background, gender and age","volume":"107","author":"Lygate","year":"2012","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2015.06.016","article-title":"Decreased creatine kinase is linked to diastolic dysfunction in rats with right heart failure induced by pulmonary artery hypertension","volume":"86","author":"Fowler","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0300","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.CIR.86.6.1810","article-title":"31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure","volume":"86","author":"Neubauer","year":"1992","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/bs.acc.2022.09.005_bb0305","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/CIRCULATIONAHA.106.613646","article-title":"Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium","volume":"114","author":"Smith","year":"2006","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/bs.acc.2022.09.005_bb0310","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/CM9.0000000000000149","article-title":"Development of heart failure risk prediction models based on a multi-marker approach using random forest algorithms","volume":"132","author":"Yuan","year":"2019","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0315","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1038\/s41598-020-61894-3","article-title":"Potential impacts of high-sensitivity creatine kinase-MB on long-term clinical outcomes in patients with stable coronary heart disease","volume":"10","author":"Wu","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0320","first-page":"877","article-title":"Development and evaluation of a new creatine kinase MB mass determination assay using a latex agglutination turbidimetric immunoassay with an automated analyzer","volume":"62","author":"Hoshino","year":"2016","journal-title":"Clin. Lab."},{"issue":"9","key":"10.1016\/bs.acc.2022.09.005_bb0325","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/clinchem\/45.9.1414","article-title":"Standardization of creatine kinase-MB (CK-MB) mass assays: the use of recombinant CK-MB as a reference material","volume":"45","author":"Obert","year":"1999","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb0330","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1515\/CCLM.2000.034","article-title":"Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB","volume":"38","author":"Okamoto","year":"2000","journal-title":"Clin. Chem. Lab. Med."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2217\/clp.13.87","article-title":"Added value of H-FABP as plasma biomarker for the early evaluation of suspected acute coronary syndrome","volume":"9","author":"Glatz","year":"2014","journal-title":"Clin Lipidol."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0340","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1253\/circj.68.144","article-title":"Office cardiologists cooperative study on whole blood rapid panel tests in patients with suspicious acute myocardial infarction: comparison between heart-type fatty acid-binding protein and troponin T tests","volume":"68","author":"Seino","year":"2004","journal-title":"Circ. J."},{"issue":"1\u20132","key":"10.1016\/bs.acc.2022.09.005_bb0345","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2012.10.016","article-title":"Critical review and meta-analysis on the combination of heart-type fatty acid binding protein (H-FABP) and troponin for early diagnosis of acute myocardial infarction","volume":"46","author":"Lippi","year":"2013","journal-title":"Clin. Biochem."},{"issue":"23","key":"10.1016\/bs.acc.2022.09.005_bb0350","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/eurheartj\/ehn363","article-title":"Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T","volume":"29","author":"McCann","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0355","article-title":"Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I","volume":"14","author":"Hoffmann","year":"2015","journal-title":"BMC Cardiovasc. Disord."},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb0360","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/07853890.2020.1800075","article-title":"Heart-type fatty acid-binding protein: an overlooked cardiac biomarker","volume":"52","author":"Goel","year":"2020","journal-title":"Ann. Med."},{"key":"10.1016\/bs.acc.2022.09.005_bb0365","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejim.2017.05.027","article-title":"A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure","volume":"44","author":"Lichtenauer","year":"2017","journal-title":"Eur. J. Intern. Med."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0370","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jjcc.2012.06.006","article-title":"Ongoing myocardial damage in patients with heart failure and preserved ejection fraction","volume":"60","author":"Kutsuzawa","year":"2012","journal-title":"J. Cardiol."},{"issue":"7","key":"10.1016\/bs.acc.2022.09.005_bb0375","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2169\/internalmedicine.53.1293","article-title":"Prognostic value of myocardial damage markers in patients with chronic heart failure with atrial fibrillation","volume":"53","author":"Otaki","year":"2014","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0380","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2261-11-41","article-title":"High sensitive troponin T and heart fatty acid binding protein: novel biomarker in heart failure with normal ejection fraction?: a cross-sectional study","volume":"11","author":"Dinh","year":"2014","journal-title":"BMC Cardiovasc. Disord."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1253\/circj.72.109","article-title":"Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure","volume":"72","author":"Niizeki","year":"2008","journal-title":"Circ. J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0390","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2018.09.004","article-title":"Persistently elevated plasma heart-type fatty acid binding protein concentration is related with poor outcome in acute decompensated heart failure patients","volume":"487","author":"Kazimierczyk","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2022.09.005_bb0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0167-4889(00)00005-7","article-title":"Myosins: a diverse superfamily","volume":"1496","author":"Sellers","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100836","article-title":"Mutations in myosin S2 alter cardiac myosin-binding protein-C interaction in hypertrophic cardiomyopathy in a phosphorylation-dependent manner","volume":"297","author":"Singh","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0405","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","article-title":"Dilated cardiomyopathy","volume":"5","author":"Schultheiss","year":"2019","journal-title":"Nat Rev Dis Primers."},{"issue":"12","key":"10.1016\/bs.acc.2022.09.005_bb0410","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/febs.13286","article-title":"Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain","volume":"282","author":"Huang","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/bs.acc.2022.09.005_bb0415","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jacc.2012.05.005","article-title":"Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure","volume":"60","author":"Piran","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0420","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1074\/jbc.M807414200","article-title":"Ablation of ventricular myosin regulatory light chain phosphorylation in mice causes cardiac dysfunction in situ and affects neighboring myofilament protein phosphorylation","volume":"284","author":"Scruggs","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/bs.acc.2022.09.005_bb0425","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1074\/jbc.RA119.011945","article-title":"Cardiac myosin regulatory light chain kinase modulates cardiac contractility by phosphorylating both myosin regulatory light chain and troponin I","volume":"295","author":"Sevrieva","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0430","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/713773607","article-title":"The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities","volume":"10","author":"De Boer","year":"2003","journal-title":"Microcirculation"},{"key":"10.1016\/bs.acc.2022.09.005_bb0435","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0440","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/eurjhf\/hft077","article-title":"Galectin-3 in heart failure with preserved ejection fraction","volume":"15","author":"de Boer","year":"2013","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0445","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"Dumic","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb0450","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1535370215593826","article-title":"Galectin-3 in autoimmunity and autoimmune diseases","volume":"240","author":"de Oliveira","year":"2015","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0455","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.acthis.2012.11.010","article-title":"The pleiotropic effects of galectin-3 in neuroinflammation: a review","volume":"115","author":"Shin","year":"2013","journal-title":"Acta Histochem."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0460","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","article-title":"The regulation of inflammation by galectin-3","volume":"230","author":"Henderson","year":"2009","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0465","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1373\/clinchem.2015.246553","article-title":"Short- and long-term biologic variability of galectin-3and other cardiac biomarkers in patients with stable heart failure and healthy adults","volume":"62","author":"Schindler","year":"2016","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0470","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann. Med."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0475","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.healun.2008.02.018","article-title":"Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices","volume":"27","author":"Milting","year":"2008","journal-title":"J. Heart Lung Transpl."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb0480","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/biom10030389","article-title":"Galectin-3 as a next-generation biomarker for detecting early stage of various diseases","volume":"10","author":"Hara","year":"2020","journal-title":"Biomolecules."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0485","first-page":"126","article-title":"Evaluation of galectin-3 as a novel diagnostic biomarker in patients with heart failure with preserved ejection fraction","volume":"12","author":"Kanukurti","year":"2020","journal-title":"J Lab Phys."},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0490","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2174\/1570161116666180703094919","article-title":"Galectin-3 and arterial stiffness in patients with heart failure: a pilot study","volume":"17","author":"Oikonomou","year":"2019","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb0495","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/eurjhf\/hfq091","article-title":"Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure","volume":"12","author":"Shah","year":"2010","journal-title":"Eur. J. Heart Fail."},{"issue":"2014","key":"10.1016\/bs.acc.2022.09.005_bb0500","first-page":"S49","article-title":"ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"129","author":"Goff","year":"2013","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201836","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction","volume":"13","author":"DuBrock","year":"2018","journal-title":"PLoS One."},{"issue":"7","key":"10.1016\/bs.acc.2022.09.005_bb0510","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ejhf.104","article-title":"C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction","volume":"16","author":"Koller","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0515","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157159","article-title":"Multi-marker strategy in heart failure: combination of ST2 and CRP predicts poor outcome","volume":"11","author":"Dupuy","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/bs.acc.2022.09.005_bb0525","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijcard.2016.11.110","article-title":"Biomarkers for characterization of heart failure \u2013 distinction of heart failure with preserved and reduced ejection fraction","volume":"227","author":"Sinning","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0530","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.020745","article-title":"Circulating cystatin C is an independent risk marker for cardiovascular outcomes, development of renal impairment, and long-term mortality in patients with stable coronary heart disease: the LIPID study","volume":"11","author":"West","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0535","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/HJH.0000000000000757","article-title":"Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism","volume":"34","author":"Huerta","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/bs.acc.2022.09.005_bb0540","article-title":"Association between cystatin C and cardiac function and long-term prognosis in patients with chronic heart failure","volume":"26","author":"Wu","year":"2020","journal-title":"Med. Sci. Monit."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0545","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/ehf2.12699","article-title":"Extracellular vesicle cystatin C and CD14 are associated with both renal dysfunction and heart failure","volume":"7","author":"Verbree-Willemsen","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb0550","first-page":"286","article-title":"Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy","volume":"10","author":"Li","year":"2013","journal-title":"J. Geriatr. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0555","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cardfail.2007.09.002","article-title":"Cystatin C concentration as a predictor of systolic and diastolic heart failure","volume":"14","author":"Moran","year":"2008","journal-title":"J. Card. Fail."},{"issue":"12","key":"10.1016\/bs.acc.2022.09.005_bb0560","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041068","article-title":"C-reactive protein at discharge and 1-year mortality in hospitalised patients with acute decompensated heart failure: an observational study","volume":"10","author":"Nishimoto","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0565","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/ehf2.13439","article-title":"Copeptin as a predictive marker of incident heart failure","volume":"8","author":"Schill","year":"2021","journal-title":"ESC Heart Fail."},{"issue":"9","key":"10.1016\/bs.acc.2022.09.005_bb0570","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/jcmm.13102","article-title":"Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis","volume":"21","author":"Yan","year":"2017","journal-title":"J. Cell. Mol. Med."},{"issue":"19","key":"10.1016\/bs.acc.2022.09.005_bb0575","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.jacc.2010.01.029","article-title":"Copeptin improves early diagnosis of acute myocardial infarction","volume":"55","author":"Keller","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0580","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023949","article-title":"Diagnostic value of copeptin combined with hypersensitive cardiac troponin T detection in early acute myocardial infarction: a protocol of randomized double-blind diagnostic trial","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0585","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12931-017-0665-z","article-title":"Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study","volume":"18","author":"Winther","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/bs.acc.2022.09.005_bb0590","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/TCRM.S124689","article-title":"Prognostic role of copeptin with all-cause mortality after heart failure: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/bs.acc.2022.09.005_bb0595","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ehf2.12231","article-title":"Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study","volume":"5","author":"D\u00fcngen","year":"2018","journal-title":"ESC Heart Fail."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0600","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/HYPERTENSIONAHA.118.10266","article-title":"Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology","volume":"71","author":"Eguchi","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/bs.acc.2022.09.005_bb0605","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1\u20137)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1\u20137)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/bs.acc.2022.09.005_bb0610","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI316","article-title":"Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell","volume":"10","author":"Leri","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2022.09.005_bb0615","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.phrs.2017.05.008","article-title":"AT1 receptor signaling pathways in the cardiovascular system","volume":"125","author":"Kawai","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/bs.acc.2022.09.005_bb0620","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardiores.2004.04.030","article-title":"TGF-beta1 and angiotensin networking in cardiac remodeling","volume":"63","author":"Rosenkranz","year":"2004","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb0625","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers","volume":"12","author":"Borovac","year":"2020","journal-title":"World J. Cardiol."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0630","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/01.CIR.88.1.136","article-title":"Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake","volume":"88","author":"Meredith","year":"1993","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014633","article-title":"Renalase deficiency in heart failure model of rats--a potential mechanism underlying circulating norepinephrine accumulation","volume":"6","author":"Gu","year":"2011","journal-title":"PLoS One."},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0640","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010887","article-title":"Association between norepinephrine levels and abnormal Iron status in patients with chronic heart failure: is Iron deficiency more than a comorbidity?","volume":"8","author":"Moliner","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0645","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.73.4.615","article-title":"Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity","volume":"73","author":"Hasking","year":"1986","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/bs.acc.2022.09.005_bb0650","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/euhj.2001.2977","article-title":"Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality","volume":"23","author":"Ceconi","year":"2002","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0655","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/eurheartj\/ehn513","article-title":"Prognostic value of circulating chromogranin A levels in acute coronary syndromes","volume":"30","author":"Jansson","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0660","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/eurjhf\/hfq055","article-title":"Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-heart failure trial","volume":"12","author":"R\u00f8sj\u00f8","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0665","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/eurheartj\/ehm022","article-title":"Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function","volume":"28","author":"Pieroni","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0670","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2008.10.012","article-title":"Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure","volume":"400","author":"Dieplinger","year":"2009","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0675","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1530\/EC-14-0017","article-title":"Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure","volume":"3","author":"Goetze","year":"2014","journal-title":"Endocr. Connect."},{"key":"10.1016\/bs.acc.2022.09.005_bb0680","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.peptides.2004.06.019","article-title":"Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients","volume":"25","author":"Struck","year":"2004","journal-title":"Peptides"},{"issue":"10","key":"10.1016\/bs.acc.2022.09.005_bb0685","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1515\/cclm-2014-0222","article-title":"Novel biomarkers in acute heart failure: MR-pro-adrenomedullin","volume":"52","author":"Peacock","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb0690","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/2048872615612455","article-title":"Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department","volume":"5","author":"Bahrmann","year":"2016","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"10","key":"10.1016\/bs.acc.2022.09.005_bb0695","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jacc.2011.06.006","article-title":"Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (biomarkers in acute heart failure) trial","volume":"58","author":"Maisel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0700","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00392-016-1066-x","article-title":"Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients","volume":"106","author":"Sinning","year":"2017","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0705","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"issue":"suppl","key":"10.1016\/bs.acc.2022.09.005_bb0710","doi-asserted-by":"crossref","first-page":"19L","DOI":"10.1016\/j.amjcard.2005.09.066","article-title":"Hyponatremia in patients with heart failure","volume":"96","author":"De Luca","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0715","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am. Heart J."},{"issue":"21","key":"10.1016\/bs.acc.2022.09.005_bb0720","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000129764.84596.EB","article-title":"Arginine vasopressin levels are elevated and correlate with functional status in infants and children with congestive heart failure","volume":"109","author":"Price","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2022.09.005_bb0725","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijcard.2005.01.043","article-title":"Possible vascular role of increased plasma arginine vasopressin in congestive heart failure","volume":"106","author":"Nakamura","year":"2006","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0730","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0300060516663779","article-title":"Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure","volume":"44","author":"Kitada","year":"2016","journal-title":"J. Int. Med. Res."},{"issue":"3\u20134","key":"10.1016\/bs.acc.2022.09.005_bb0735","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000501100","article-title":"Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension","volume":"143","author":"Chowdhury","year":"2019","journal-title":"Cardiology"},{"issue":"11","key":"10.1016\/bs.acc.2022.09.005_bb0740","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003381","article-title":"Dual endothelin-a\/endothelin-B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction","volume":"9","author":"Valero-Munoz","year":"2016","journal-title":"Circ. Heart Fail."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0745","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ajcp\/aqx014","article-title":"Systematic evaluation of endothelin 1 measurement relative to traditional and modern biomarkers for clinical assessment and prognosis in patients with chronic systolic heart failure: serial measurement and multimarker testing","volume":"147","author":"Gaggin","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0750","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamacardio.2016.0962","article-title":"Association of elevated plasma endothelin-1 levels with pulmonary hypertension, mortality, and heart failure in African American individuals: the Jackson heart study","volume":"1","author":"Jankowich","year":"2016","journal-title":"JAMA Cardiol."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014506","article-title":"Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-Endothelin-1","volume":"6","author":"Jankowska","year":"2011","journal-title":"PLoS ONE."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0760","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1002\/ehf2.13064","article-title":"Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure","volume":"7","author":"Zymli\u0144ski","year":"2020","journal-title":"ESC Heart Failure"},{"issue":"50","key":"10.1016\/bs.acc.2022.09.005_bb0765","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009342","article-title":"Plasma endothelin-1-related peptides as the prognostic biomarkers for heart failure: a PRISMA-compliant meta-analysis","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/bs.acc.2022.09.005_bb0770","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.000080","article-title":"Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult mammalian heart","volume":"6","author":"Divakaran","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0775","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.CIR.93.4.704","article-title":"Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart","volume":"93","author":"Torre-Amione","year":"1996","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0780","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099495","article-title":"Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction","volume":"9","author":"Putko","year":"2014","journal-title":"PLos ONE."},{"key":"10.1016\/bs.acc.2022.09.005_bb0785","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","article-title":"Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study","volume":"107","author":"Vasan","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/bs.acc.2022.09.005_bb0790","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCA.0b013e3283093707","article-title":"The role of Fas in the progression of ischemic heart failure: prohypertrophy or proapoptosis","volume":"19","author":"Feng","year":"2008","journal-title":"Coron. Artery Dis."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0795","first-page":"810","article-title":"Myocardial expression of Fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy","volume":"40","author":"Sheppard","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0800","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/01.RES.0000141528.54850.bd","article-title":"Critical roles for the Fas\/Fas ligand system in postinfarction ventricular remodeling and heart failure","volume":"95","author":"Li","year":"2004","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0805","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.yjmcc.2006.03.010","article-title":"Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1","volume":"40","author":"Niu","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb0810","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1752-8062.2008.00056.x","article-title":"Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support","volume":"1","author":"Bedi","year":"2008","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/bs.acc.2022.09.005_bb0815","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.ATV.0000204334.48195.6a","article-title":"Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization","volume":"26","author":"Sandberg","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0820","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jacc.2004.06.076","article-title":"Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction","volume":"44","author":"Ueland","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0825","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/HYPERTENSIONAHA.107.087742","article-title":"Plasma osteoprotegerin levels in the general population relation to indices of left ventricular structure and function","volume":"49","author":"Omland","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/bs.acc.2022.09.005_bb0830","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jacc.2007.09.058","article-title":"Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes","volume":"51","author":"Omland","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0835","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCHEARTFAILURE.110.957332","article-title":"Osteoprotegerin predicts progression of chronic heart failure: results from CORONA","volume":"4","author":"Ueland","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb0840","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.104.530972","article-title":"Adiponectin, body mass index, and mortality in patients with chronic heart failure","volume":"112","author":"Kistorp","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2022.09.005_bb0845","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jacc.2008.07.073","article-title":"Resistin, adiponectin, and risk of heart failure the Framingham offspring study","volume":"53","author":"Frankel","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0850","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCHEARTFAILURE.109.885525","article-title":"Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure","volume":"3","author":"Van Berendoncks","year":"2010","journal-title":"Circ. Heart Fail."},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0855","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/oby.20260","article-title":"Association between adiponectin and heart failure risk in the physicians' health study","volume":"21","author":"Djouss\u00e9","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/bs.acc.2022.09.005_bb0860","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1475-2840-11-151","article-title":"Adiponectin, diabetes and ischemic heart failure: a challenging relationship","volume":"11","author":"Baldasseroni","year":"2012","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0865","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jacc.2015.07.035","article-title":"A novel collagen matricryptin reduces left ventricular dilation post-myocardial infarction by promoting scar formation and angiogenesis","volume":"66","author":"Lindsey","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb0870","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ehf2.12137","article-title":"Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure","volume":"4","author":"Morishita","year":"2017","journal-title":"ESC Heart Fail."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0875","first-page":"223","article-title":"Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics","volume":"7","author":"Ahmed","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"7","key":"10.1016\/bs.acc.2022.09.005_bb0880","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011426","article-title":"Association of circulating tissue inhibitor of metalloproteinases-1 and procollagen type III Aminoterminal peptide levels with incident heart failure and chronic kidney disease","volume":"8","author":"Lieb","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0885","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cardfail.2004.01.010","article-title":"Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure","volume":"10","author":"Cicoira","year":"2014","journal-title":"J. Card. Fail."},{"issue":"9","key":"10.1016\/bs.acc.2022.09.005_bb0890","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.cardfail.2015.12.016","article-title":"Circulating procollagen type III N-terminal peptide and mortality risk in African Americans with heart failure","volume":"22","author":"Mansour","year":"2012","journal-title":"J. Card. Fail."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0895","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/CIRCHEARTFAILURE.111.962027","article-title":"The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the cardiovascular health study","volume":"4","author":"Barasch","year":"2011","journal-title":"Circ. Heart Fail."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0900","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.amjcard.2006.04.018","article-title":"Plasma myeloperoxidase levels in patients with chronic heart failure","volume":"98","author":"Tang","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0905","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0891-5849(00)00229-X","article-title":"Myeloperoxidase-generated oxidants and atherosclerosis","volume":"28","author":"Podrez","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/bs.acc.2022.09.005_bb0910","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity","volume":"320","author":"Steinberg","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.09.005_bb0915","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI200421109","article-title":"Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease","volume":"114","author":"Zheng","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2022.09.005_bb0920","doi-asserted-by":"crossref","first-page":"42977","DOI":"10.1074\/jbc.M406762200","article-title":"Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species","volume":"279","author":"Pennathur","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/bs.acc.2022.09.005_bb0925","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1161\/CIRCULATIONAHA.105.542340","article-title":"Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction","volume":"112","author":"Vasilyev","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0930","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.amjcard.2006.04.018","article-title":"Plasma myeloperoxidase levels in patients with chronic heart failure","volume":"98","author":"Tang","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0935","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000368717","article-title":"Serum myeloperoxidase level is associated with heart-type fatty acid-binding protein but not troponin T in patients with chronic heart failure","volume":"24","author":"Gedikli","year":"2015","journal-title":"Med Princip Pract"},{"key":"10.1016\/bs.acc.2022.09.005_bb0940","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0735-1097(02)01721-7","article-title":"Plasma oxidized low-density lipoprotein as a prognostic predictor in subjects with chronic congestive heart failure","volume":"39","author":"Tsutsui","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2022.09.005_bb0945","doi-asserted-by":"crossref","first-page":"C165","DOI":"10.1152\/ajpcell.00116.2011","article-title":"Induction of brain natriuretic peptide and monocyte chemotactic protein-1 gene expression by oxidized low-density lipoprotein: relevance to ischemic heart failure","volume":"302","author":"Chandrakala","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb0950","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12726","article-title":"Increased presence of oxidized low-density lipoprotein in the left ventricular blood of subjects with cardiovascular disease","volume":"4","author":"Aluganti Narasimhulu","year":"2016","journal-title":"Physiol. Rep."},{"issue":"10","key":"10.1016\/bs.acc.2022.09.005_bb0955","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.5551\/jat.43299","article-title":"Circulating oxidized low-density lipoprotein levels independently predict 10-year progression of subclinical carotid atherosclerosis: a community-based cohort study","volume":"25","author":"Gao","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"issue":"10","key":"10.1016\/bs.acc.2022.09.005_bb0960","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jacc.2004.01.028","article-title":"Urinary biopyrrins levels are elevated in relation to severity of heart failure","volume":"43","author":"Hokamaki","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/bs.acc.2022.09.005_bb0965","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0002-9149(02)02430-X","article-title":"Comparison of urinary biopyrrin levels in acute myocardial infarction (after reperfusion therapy) versus stable angina pectoris and their usefulness in predicting subsequent cardiac events","volume":"90","author":"Shimomura","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb0970","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.freeradbiomed.2010.11.023","article-title":"F2-isoprostanes as an indicator and risk factor for coronary heart disease","volume":"50","author":"Davies","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0975","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cardfail.2003.11.004","article-title":"Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity","volume":"10","author":"Polidori","year":"2004","journal-title":"J. Card. Fail."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0980","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0002-8703(96)90063-0","article-title":"Increased malondialdehyde in peripheral blood of patients with congestive heart failure","volume":"131","author":"D\u00edaz-V\u00e9lez","year":"1996","journal-title":"Am. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb0985","article-title":"Malondialdehyde and uric acid as predictors of adverse outcome in patients with chronic heart failure","volume":"9246138","author":"Romuk","year":"2019","journal-title":"Oxidative Medand Cell Longevity"},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb0990","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/CIRCHEARTFAILURE.109.867747","article-title":"Chromogranin B in heart failure: a putative cardiac biomarker expressed in the failing myocardium","volume":"3","author":"R\u00f8sj\u00f8","year":"2010","journal-title":"Circ. Heart Fail."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb0995","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/1354750X.2017.1395079","article-title":"Regulation of circulating chromogranin B levels in heart failure","volume":"23","author":"Heidrich","year":"2018","journal-title":"Biomarkers"},{"issue":"10","key":"10.1016\/bs.acc.2022.09.005_bb1000","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCRESAHA.107.166033","article-title":"Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes","volume":"102","author":"Heidrich","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2022.09.005_bb1005","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/1354750X.2011.629058","article-title":"Catestatin is useful in detecting patients with stage B heart failure","volume":"16","author":"Zhu","year":"2011","journal-title":"Biomarkers"},{"issue":"7","key":"10.1016\/bs.acc.2022.09.005_bb1010","doi-asserted-by":"crossref","first-page":"44168","DOI":"10.1038\/srep44168","article-title":"Catestatin-a novel predictor of left ventricular remodeling after acute myocardial infarction","volume":"11","author":"Zhu","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb1015","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/jcm8081132","article-title":"Catestatin in acutely decompensated heart failure patients: insights from the CATSTAT-HF study","volume":"8","author":"Borovac","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/bs.acc.2022.09.005_bb1020","first-page":"8847211","article-title":"Catestatin as a new prognostic marker in stable patients with heart failure with reduced ejection fraction in two-year follow-up","author":"Wo\u0142owiec","year":"2020","journal-title":"Dis Mark."},{"key":"10.1016\/bs.acc.2022.09.005_bb1025","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1002\/ehf2.12882","article-title":"Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study","volume":"7","author":"Borovac","year":"2020","journal-title":"ESC Heart Failure"},{"key":"10.1016\/bs.acc.2022.09.005_bb1030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.peptides.2013.05.003","article-title":"Plasma levels and diagnostic value of catestatin in patients with heart failure","volume":"46","author":"Liu","year":"2013","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/bs.acc.2022.09.005_bb1035","first-page":"501","article-title":"The genetics of cardiac failure: role of a G protein-coupled receptor polymorphism in therapeutic response in an Indian population","volume":"7","author":"Ramalingam","year":"2021","journal-title":"J. Clin. Transl. Res"},{"issue":"8","key":"10.1016\/bs.acc.2022.09.005_bb1040","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600800","article-title":"Loss-of-function variants influence the human serum metabolome","volume":"2","author":"Yu","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/bs.acc.2022.09.005_bb1045","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O'Brien","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/bs.acc.2022.09.005_bb1050","doi-asserted-by":"crossref","first-page":"18255","DOI":"10.1073\/pnas.0608791103","article-title":"A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure","volume":"103","author":"van Rooij","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2022.09.005_bb1055","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1128\/MCB.01222-08","article-title":"MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes","volume":"29","author":"Ikeda","year":"2009","journal-title":"Mol. Cell. Biol."},{"issue":"14","key":"10.1016\/bs.acc.2022.09.005_bb1060","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1242\/jcs.067165","article-title":"Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy","volume":"123","author":"Li","year":"2010","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb1065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCRESAHA.109.212183","article-title":"The role of microRNA-133 in cardiac hypertrophy uncovered","volume":"106","author":"Abdellatif","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2022.09.005_bb1070","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nm1582","article-title":"MicroRNA-133 controls cardiac hypertrophy","volume":"13","author":"Car\u00e8","year":"2007","journal-title":"Nat. Med."},{"issue":"5824","key":"10.1016\/bs.acc.2022.09.005_bb1075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1126\/science.1139089","article-title":"Control of stress-dependent cardiac growth and gene expression by a microRNA","volume":"316","author":"van Rooij","year":"2007","journal-title":"Science"},{"issue":"16","key":"10.1016\/bs.acc.2022.09.005_bb1080","doi-asserted-by":"crossref","first-page":"12913","DOI":"10.1074\/jbc.M111.331751","article-title":"A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival","volume":"287","author":"Knezevic","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/bs.acc.2022.09.005_bb1085","doi-asserted-by":"crossref","first-page":"11216","DOI":"10.1074\/jbc.M112.442384","article-title":"A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling","volume":"288","author":"Nagalingam","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.acc.2022.09.005_bb1090","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41467-017-01737-4","article-title":"Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling","volume":"8","author":"Sassi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.acc.2022.09.005_bb1095","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1073\/pnas.0805038105","article-title":"Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis","volume":"105","author":"van Rooij","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/bs.acc.2022.09.005_bb1100","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.ijcard.2012.07.021","article-title":"Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients","volume":"167","author":"Villar","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"9","key":"10.1016\/bs.acc.2022.09.005_bb1105","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1111\/j.1582-4934.2012.01523.x","article-title":"MicroRNA-24 regulates cardiac fibrosis after myocardial infarction","volume":"16","author":"Wang","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/bs.acc.2022.09.005_bb1110","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1093\/eurheartj\/eht256","article-title":"Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure","volume":"34","author":"Vogel","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.09.005_bb1115","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1161\/CIRCRESAHA.110.218297","article-title":"MiR423-5p as a circulating biomarker for heart failure","volume":"106","author":"Tijsen","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2022.09.005_bb1120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/eurjhf\/hfr155","article-title":"Serum levels of microRNAs in patients with heart failure","volume":"14","author":"Oren","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/bs.acc.2022.09.005_bb1125","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.21037\/jtd.2018.10.52","article-title":"Circulating exosomal MiR-92b-5p is a promising diagnostic biomarker of heart failure with reduced ejection fraction patients hospitalized for acute heart failure","volume":"10","author":"Wu","year":"2018","journal-title":"J. Thor. Dis."},{"key":"10.1016\/bs.acc.2022.09.005_bb1130","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/458a1f6a-6327-429a-81cb-992c97f04bd6","article-title":"A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction","volume":"8","author":"Devaux","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.acc.2022.09.005_bb1135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1160\/TH12-02-0097","article-title":"Analytical challenges and technical limitations in assessing circulating miRNAs","volume":"108","author":"Zampetaki","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.09.005_bb1140","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCRESAHA.114.303915","article-title":"Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure","volume":"114","author":"Kumarswamy","year":"2014","journal-title":"Circ. Res."},{"issue":"29","key":"10.1016\/bs.acc.2022.09.005_bb1145","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019703","article-title":"Association of long-chain non-coding RNA MHRT gene single nucleotide polymorphism with risk and prognosis of chronic heart failure","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltimore)."},{"issue":"36","key":"10.1016\/bs.acc.2022.09.005_bb1150","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1093\/eurheartj\/ehaa519","article-title":"Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy","volume":"41","author":"Viereck","year":"2020","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/bs.acc.2022.09.005_bb1155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nbt.2890","article-title":"Detecting and characterizing circular RNAs","volume":"32","author":"Jeck","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb1160","first-page":"298","article-title":"A landscape of circular RNA expression in the human heart","volume":"113","author":"Tan","year":"2017","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb1165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151753","article-title":"The circular RNA Cdr1as promotes myocardial infarction by mediating the regulation of miR-7a on its target genes expression","volume":"11","author":"Geng","year":"2016","journal-title":"PLoS One."},{"issue":"11","key":"10.1016\/bs.acc.2022.09.005_bb1170","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jacc.2016.06.040","article-title":"Myocardial infarction-associated circular RNA predicting left ventricular dysfunction","volume":"68","author":"Vausort","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/bs.acc.2022.09.005_bb1175","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.119.314937","article-title":"Comparative analysis of circulating noncoding RNAs versus protein biomarkers in the detection of myocardial injury","volume":"125","author":"Schulte","year":"2019","journal-title":"Circ. Res."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:08:35Z","timestamp":1673608115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242322000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443192845"],"references-count":234,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2022.09.005","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}